|
Lymphocyte Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
The combination of a genome-wide association study of lymphocyte count and analysis of gene expression data reveals novel asthma candidate genes.
|
22286170 |
2012 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
In GDC-0084-treated tumor tissues PI3K-Akt-mTOR and DNA-PKcs activation were significantly inhibited.
|
30072096 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Treatment with the combination of fulvestrant and GDC-0941, regardless of dose/schedule, was significantly more effective than that with single-agent treatments in fulvestrant-resistant tumors.
|
26733612 |
2016 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Further, we used this model to test the efficacy of GDC-0941, a PI3K inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition.
|
22370636 |
2013 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
GDC-0449 is a novel first-in-human, first-in-class smoothened (SMO) inhibitor, which has completed its phase I evaluation and achieved proof of concept in tumors with Hh pathway mutations.
|
21367749 |
2011 |
|
Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
Whereas GDC-0879-mediated efficacy was associated strictly with BRAF(V600E) status, MEK inhibition also attenuated proliferation and tumor growth of cell lines expressing wild-type BRAF (81% KRAS mutant, 38% KRAS wild type).
|
19276360 |
2009 |
|
Malignant neoplasm of breast
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
For newly-diagnosed breast cancer, the association between VWF and histology in the GDC Breast Cancer dataset in The Cancer Genome Atlas (TCGA) was evaluated.
|
31018945 |
2019 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
These results correspond with our analysis of the melanoma survival rates (SRs) from Human Protein Atlas and The Cancer Genome Atlas GDC (362 patients), where low <i>ER</i>β expression in melanoma correlate with a poor relapse-free survival, and no correlations were observed between SRs and <i>ER</i>α or <i>GPER</i> expression in melanoma.
|
31696058 |
2019 |
|
Breast Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
For newly-diagnosed breast cancer, the association between VWF and histology in the GDC Breast Cancer dataset in The Cancer Genome Atlas (TCGA) was evaluated.
|
31018945 |
2019 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
These results correspond with our analysis of the melanoma survival rates (SRs) from Human Protein Atlas and The Cancer Genome Atlas GDC (362 patients), where low <i>ER</i>β expression in melanoma correlate with a poor relapse-free survival, and no correlations were observed between SRs and <i>ER</i>α or <i>GPER</i> expression in melanoma.
|
31696058 |
2019 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Intriguingly, GDC-0941-resistant breast cancer cells remained sensitive to KDM6B or IGFBP5 inhibition, indicating the dependency on the KDM6B-IGFBP5 axis to confer the survival advantage in GDC-0941-resistant cells.
|
29925528 |
2018 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
We applied ANF to a processed harmonized cancer dataset downloaded from GDC data portal consisting of 2193 patients, and generated promising results on clustering patients into correct disease types.
|
29807109 |
2018 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Intriguingly, GDC-0941-resistant breast cancer cells remained sensitive to KDM6B or IGFBP5 inhibition, indicating the dependency on the KDM6B-IGFBP5 axis to confer the survival advantage in GDC-0941-resistant cells.
|
29925528 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
We applied ANF to a processed harmonized cancer dataset downloaded from GDC data portal consisting of 2193 patients, and generated promising results on clustering patients into correct disease types.
|
29807109 |
2018 |
|
Carcinoma, Basal Cell
|
0.020 |
Biomarker
|
disease |
BEFREE |
GDC‑0449, a basal cell skin cancer target drug approved by the Food and Drugs Administration, is a smoothened (Smo)-specific antagonist.
|
26676867 |
2016 |
|
Medulloblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
GDC-0449 has an acceptable safety profile and encouraging anti-tumor activity in advanced BCC and medulloblastoma.
|
21300762 |
2011 |
|
Childhood Medulloblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
GDC-0449 has an acceptable safety profile and encouraging anti-tumor activity in advanced BCC and medulloblastoma.
|
21300762 |
2011 |
|
Adult Medulloblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
GDC-0449 has an acceptable safety profile and encouraging anti-tumor activity in advanced BCC and medulloblastoma.
|
21300762 |
2011 |
|
Carcinoma, Basal Cell
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thirty-three of 68 patients had advanced basal cell carcinoma (BCC), 8 had pancreatic cancer, 1 had medulloblastoma; 17 other types of cancer were also represented.GDC-0449 was generally well-tolerated.
|
21300762 |
2011 |
|
Medulloblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
A mutation altering the same amino acid also arose in a GDC-0449-resistant mouse model of medulloblastoma.
|
19726788 |
2009 |
|
Childhood Medulloblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
A mutation altering the same amino acid also arose in a GDC-0449-resistant mouse model of medulloblastoma.
|
19726788 |
2009 |
|
Adult Medulloblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
A mutation altering the same amino acid also arose in a GDC-0449-resistant mouse model of medulloblastoma.
|
19726788 |
2009 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results correspond with our analysis of the melanoma survival rates (SRs) from Human Protein Atlas and The Cancer Genome Atlas GDC (362 patients), where low <i>ER</i>β expression in melanoma correlate with a poor relapse-free survival, and no correlations were observed between SRs and <i>ER</i>α or <i>GPER</i> expression in melanoma.
|
31696058 |
2019 |
|
Pancreatic carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A frontline chemotherapy used for pancreatic cancer, i.e., gemcitabine (GEM) and a Hedgehog inhibitor (GDC 0449) has been used as the model combination to evaluate the encapsulation and pH-dependent release efficiency of these block copolymers.
|
30447521 |
2019 |
|
Malignant neoplasm of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
A frontline chemotherapy used for pancreatic cancer, i.e., gemcitabine (GEM) and a Hedgehog inhibitor (GDC 0449) has been used as the model combination to evaluate the encapsulation and pH-dependent release efficiency of these block copolymers.
|
30447521 |
2019 |